JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathiesGina A. Montealegre Sanchez, Jonathan Janes, Adam Reinhardt et al.|Journal of Clinical Investigation|2018Cited by 519
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)Michelle Petri, Marta Mosca, Mario H. Cardiel et al.|The Lancet|2023Cited by 164
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)Eric F. Morand, Thomas Dörner, Edward M Vital et al.|The Lancet|2023Cited by 151